Qing Zhang

I got my PhD in Pathology from Univ. of Pittsburgh studying role of N-glycosylation in MHC class I biosynthesis. Towards the end of my PhD years I got bitten by the computer bug working on sequence analysis and pattern recognition to identify antigenic peptides presented by MHC class I molecules. After a postdoc at Columbia Univ. on small GTPases in phagocytosis, I joined Celera Genomics in 1998 and worked on drosophila, human and mouse genomes. While at Celera I also obtained a MS in Computer Sciences majoring in software engineering and bioinformatics from Johns Hopkins Univ.

In 2003 I joined Schering Plough. I provided bioinformatics support across various therapeutic areas and was involved in using bioinformatics approaches to find the drug target for a cholesterol absorption inhibitor post-approval. After the Merck merger, I became the bioinformatics/biomarker representative for the anti-PD1 (known as MK-3475 then) clinical trial team when it first went into patients in 2011. I also worked at Regeneron prior to joining Genentech, leading their Molecular Profiling and Bioinformatics effort supporting Oncology across the pipeline including discovery, dev sci, translational and clinical.

I joined Genentech in 2014 as a Sr. Scientist (bioinformatics) in Antibody Engineering. My group builds computational tools and pipelines, and performs data analysis to support Antibody Engineering. We also have joint appointments with the Bioinformatics & Computational Biology group, collaborating with B&CB colleagues revamping software infrastructure that supports Protein Sciences.